XML 50 R37.htm IDEA: XBRL DOCUMENT
v3.8.0.1

Revenues - Revenues Disaggregated by Significant Customer (Details) - USD ($) $ in Thousands | 3 Months Ended
--- | ---
Mar. 30, 2018 | Mar. 31, 2017
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] |  |
Total revenues | $ 212,346 | $ 80,887
Ipsen |  |
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] |  |
Total revenues | $ 53,809 | $ 4,530
Ipsen | Revenue | Customer Concentration Risk |  |
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] |  |
Percent of total revenues | 25.00% | 6.00%
Caremark L.L.C. |  |
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] |  |
Total revenues | $ 26,388 | $ 13,819
Caremark L.L.C. | Revenue | Customer Concentration Risk |  |
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] |  |
Percent of total revenues | 12.00% | 17.00%
Affiliates of McKesson Corporation |  |
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] |  |
Total revenues | $ 21,331 | $ 11,278
Affiliates of McKesson Corporation | Revenue | Customer Concentration Risk |  |
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] |  |
Percent of total revenues | 10.00% | 14.00%
Diplomat Specialty Pharmacy |  |
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] |  |
Total revenues | $ 20,147 | $ 19,850
Diplomat Specialty Pharmacy | Revenue | Customer Concentration Risk |  |
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] |  |
Percent of total revenues | 9.00% | 25.00%
Accredo Health, Incorporated |  |
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] |  |
Total revenues | $ 18,286 | $ 9,440
Accredo Health, Incorporated | Revenue | Customer Concentration Risk |  |
Revenue, Initial Application Period Cumulative Effect Transition [Line Items] |  |
Percent of total revenues | 9.00% | 12.00%

X
- Definition For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -URI http://asc.fasb.org/extlink&oid=84177426&loc=d3e6351-108592 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=77997519&loc=d3e13531-108611 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=84177426&loc=d3e6404-108592 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=77997519&loc=d3e13537-108611 + Details
Name: | us-gaap_ConcentrationRiskPercentage1
Namespace Prefix: | us-gaap_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1) -URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688 + Details
Name: | us-gaap_Revenues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_MajorCustomersAxis=exel_IpsenMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueGoodsNetMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_MajorCustomersAxis=exel_CaremarkL.L.C.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_MajorCustomersAxis=exel_AffiliatesofMcKessonCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_MajorCustomersAxis=exel_DiplomatSpecialtyPharmacyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_MajorCustomersAxis=exel_AccredoHealthIncorporatedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |